All news

Samsung Biologics secures 97.66% of PolyPeptide in CHF 1.46 billion tender offer

BioPharm International · · AI-summarised by FinFlash

Samsung Biologics, through its Swiss unit Samsung Peptide AG, has provisionally secured 97.66% of PolyPeptide Group after the additional acceptance period ended October 30, with 32,350,302 shares tendered at CHF 44.31 each in cash. The deal values the peptide drugmaker at about CHF 1.46 billion. Definitive results are due November 5; settlement, first set for November 13, is delayed pending regulatory approvals.

So What?

The stake clears the way for a squeeze-out and SIX delisting by end-2026 or Q1 2027. It gives Samsung peptide API capacity, including GLP-1 exposure.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.